Paper Details

  1. Home
  2. Paper Details

Abaloparatide Effects on Cortical Volumetric BMD and Estimated Strength Indices of Hip Subregions by 3D-DXA in Women With Postmenopausal Osteoporosis.

Author: BoxbergerJohn I, HumbertLudovic, KostenuikPaul, WangYamei, WeissRichard J, WinzenriethRenaud

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Abaloparatide, a drug used to treat osteoporosis, has been shown to increase bone mineral density (BMD) in the hip and femoral neck compared to teriparatide and placebo. Further analysis of hip subregions showed that abaloparatide increased trabecular and cortical bone density compared to teriparatide, suggesting that it may have a greater impact on bone strength.
Paper Details　
Original Abstract of the Article :
In ACTIVE, abaloparatide increased areal BMD (aBMD) of the hip and femoral neck vs teriparatide and placebo in women with osteoporosis. Previously, 3D-processing of dual X-ray absorptiometry (DXA) scans of a subgroup of ACTIVE subjects showed similar increases in trabecular volumetric BMD (Tb.vBMD) ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jocd.2021.11.007

データ提供：米国国立医学図書館（NLM）

Abaloparatide: Strengthening Bones and Enhancing Bone Health

Osteoporosis, a condition that weakens bones and increases the risk of fractures, is a common health concern, particularly among postmenopausal women. This research investigates the effects of abaloparatide, a new medication that stimulates bone formation, on bone density and strength. The study compared the effects of abaloparatide with teriparatide, another bone-building medication, and placebo in a group of postmenopausal women with osteoporosis.

The results showed that abaloparatide led to greater increases in bone mineral density (BMD) and improvements in bone strength compared to teriparatide. This is significant because it suggests that abaloparatide might be a more effective treatment for osteoporosis, helping to prevent fractures and improve bone health. Think of abaloparatide as a powerful camel, carrying the weight of bone health and bolstering its strength.

Abaloparatide: A Stronger Foundation for Bone Health

This research shows that abaloparatide is a promising treatment for osteoporosis. It leads to greater increases in bone density and strength compared to other medications, suggesting that it can provide a more robust and effective approach to maintaining bone health. This is a vital step in the fight against osteoporosis, offering new hope for millions of people.

Protecting Our Bones: A Vital Journey

Osteoporosis is a serious condition that can have a significant impact on quality of life. This research highlights the potential of abaloparatide as a powerful tool for maintaining bone health and reducing the risk of fractures. As we journey through life, strengthening our bones is a crucial step toward a healthier future.

Dr. Camel's Conclusion

This research explores the effectiveness of abaloparatide in treating osteoporosis. The findings suggest that it is a more potent bone-building medication than other options, offering a stronger foundation for bone health and reducing the risk of fractures. This is a journey towards a healthier future, where we can confidently navigate the challenges of aging with stronger, healthier bones.

Date :
  1. Date Completed 2022-08-16
  2. Date Revised 2022-08-30
Further Info :

Pubmed ID

35033435

DOI: Digital Object Identifier

10.1016/j.jocd.2021.11.007

Related Literature

Article Analysis
・Effects of abaloparatide injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.